MORF - Morphic shows dose-dependent effect of inflammatory bowel disease therapy in Phase 1 trial

Morphic Therapeutic (MORF) said that MORF-057, an oral small-molecule inhibitor of the ?4?7 showed dose-dependent receptor occupancy in a Phase 1 trial for inflammatory bowel disease ((IBD)).The results were shared in a presentation at the Congress ((CACOX)) of the European Crohn’s and Colitis Organisation ((ECCO)) 2021 Virtual Congress.The study involving 67 healthy subjects included single ascending dose ((SAD)), multiple ascending dose ((MAD)), and food effect ((FE)) cohorts.The drug was well tolerated across all cohorts with no safety signals, the company said. Only one person from the 50 mg BID MAD cohort has withdrawn the consent due to personal reasons. Others have completed the study.?4?7 receptor occupancy has risen with dose and study day, reaching saturation from all cohorts above 25 mg by day 14. “In the 100 mg BID cohort, MORF-057 saturated the ?4?7 receptor (mean RO >99%),” Morphic noted in the statement.A conference call on results is scheduled at 8:00 AM

For further details see:

Morphic shows dose-dependent effect of inflammatory bowel disease therapy in Phase 1 trial